202 related articles for article (PubMed ID: 22110122)
1. The association of treatment response and joint damage with ACPA-status in recent-onset RA: a subanalysis of the 8-year follow-up of the BeSt study.
van den Broek M; Dirven L; Klarenbeek NB; Molenaar TH; Han KH; Kerstens PJ; Huizinga TW; Dijkmans BA; Allaart CF
Ann Rheum Dis; 2012 Feb; 71(2):245-8. PubMed ID: 22110122
[TBL] [Abstract][Full Text] [Related]
2. Should we redefine treatment targets in rheumatoid arthritis? Low disease activity is sufficiently strict for patients who are anticitrullinated protein antibody-negative.
de Punder YM; Hendrikx J; den Broeder AA; Valls Pascual E; van Riel PL; Fransen J
J Rheumatol; 2013 Aug; 40(8):1268-74. PubMed ID: 23729803
[TBL] [Abstract][Full Text] [Related]
3. Progression of joint damage in early rheumatoid arthritis: association with HLA-DRB1, rheumatoid factor, and anti-citrullinated protein antibodies in relation to different treatment strategies.
de Vries-Bouwstra JK; Goekoop-Ruiterman YP; Verpoort KN; Schreuder GM; Ewals JA; Terwiel JP; Ronday HK; Kerstens PJ; Toes RE; de Vries RR; Breedveld FC; Dijkmans BA; Huizinga TW; Allaart CF
Arthritis Rheum; 2008 May; 58(5):1293-8. PubMed ID: 18438829
[TBL] [Abstract][Full Text] [Related]
4. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis.
van der Linden MP; van der Woude D; Ioan-Facsinay A; Levarht EW; Stoeken-Rijsbergen G; Huizinga TW; Toes RE; van der Helm-van Mil AH
Arthritis Rheum; 2009 Aug; 60(8):2232-41. PubMed ID: 19644872
[TBL] [Abstract][Full Text] [Related]
5. The ACPA recognition profile and subgrouping of ACPA-positive RA patients.
Willemze A; Böhringer S; Knevel R; Levarht EW; Stoeken-Rijsbergen G; Houwing-Duistermaat JJ; van der Helm-van Mil AH; Huizinga TW; Toes RE; Trouw LA
Ann Rheum Dis; 2012 Feb; 71(2):268-74. PubMed ID: 21998120
[TBL] [Abstract][Full Text] [Related]
6. Sustained drug-free remission in rheumatoid arthritis after DAS-driven or non-DAS-driven therapy: a comparison of two cohort studies.
van der Woude D; Visser K; Klarenbeek NB; Ronday HK; Peeters AJ; Kerstens PJ; Dijkmans BA; Huizinga TW; van der Helm-van Mil AH; Allaart CF
Rheumatology (Oxford); 2012 Jun; 51(6):1120-8. PubMed ID: 22337939
[TBL] [Abstract][Full Text] [Related]
7. Determinants of reaching drug-free remission in patients with early rheumatoid or undifferentiated arthritis after one year of remission-steered treatment.
Wevers-de Boer KV; Heimans L; Visser K; Schouffoer AA; Molenaar ET; van Groenendael JH; Peeters AJ; Speyer I; Collée G; Huizinga TW; Allaart CF
Rheumatology (Oxford); 2015 Aug; 54(8):1380-4. PubMed ID: 25687553
[TBL] [Abstract][Full Text] [Related]
8. Treatment of recent-onset rheumatoid arthritis: lessons from the BeSt study.
Allaart CF; Breedveld FC; Dijkmans BA
J Rheumatol Suppl; 2007 Nov; 80():25-33. PubMed ID: 17985420
[TBL] [Abstract][Full Text] [Related]
9. Association with joint damage and physical functioning of nine composite indices and the 2011 ACR/EULAR remission criteria in rheumatoid arthritis.
Klarenbeek NB; Koevoets R; van der Heijde DM; Gerards AH; Ten Wolde S; Kerstens PJ; Huizinga TW; Dijkmans BA; Allaart CF
Ann Rheum Dis; 2011 Oct; 70(10):1815-21. PubMed ID: 21813548
[TBL] [Abstract][Full Text] [Related]
10. The value of rheumatoid factor and anti-citrullinated protein antibodies as predictors of response to infliximab in rheumatoid arthritis: an exploratory study.
Klaasen R; Cantaert T; Wijbrandts CA; Teitsma C; Gerlag DM; Out TA; de Nooijer MJ; Baeten D; Tak PP
Rheumatology (Oxford); 2011 Aug; 50(8):1487-93. PubMed ID: 21454308
[TBL] [Abstract][Full Text] [Related]
11. Discontinuation of infliximab and potential predictors of persistent low disease activity in patients with early rheumatoid arthritis and disease activity score-steered therapy: subanalysis of the BeSt study.
van den Broek M; Klarenbeek NB; Dirven L; van Schaardenburg D; Hulsmans HM; Kerstens PJ; Huizinga TW; Dijkmans BA; Allaart CF
Ann Rheum Dis; 2011 Aug; 70(8):1389-94. PubMed ID: 21515916
[TBL] [Abstract][Full Text] [Related]
12. Anticitrullinated protein antibodies and rheumatoid factor fluctuate in early inflammatory arthritis and do not predict clinical outcomes.
Barra L; Bykerk V; Pope JE; Haraoui BP; Hitchon CA; Thorne JC; Keystone EC; Boire G;
J Rheumatol; 2013 Aug; 40(8):1259-67. PubMed ID: 23378461
[TBL] [Abstract][Full Text] [Related]
13. Five-year outcomes of probable rheumatoid arthritis treated with methotrexate or placebo during the first year (the PROMPT study).
van Aken J; Heimans L; Gillet-van Dongen H; Visser K; Ronday HK; Speyer I; Peeters AJ; Huizinga TW; Allaart CF
Ann Rheum Dis; 2014 Feb; 73(2):396-400. PubMed ID: 23334213
[TBL] [Abstract][Full Text] [Related]
14. Anti-citrullinated peptide antibodies and the progression of radiographic joint erosions in patients with early rheumatoid arthritis treated with FIN-RACo combination and single disease-modifying antirheumatic drug strategies.
Mustila A; Korpela M; Haapala AM; Kautiainen H; Laasonen L; Möttönen T; Leirisalo-Repo M; Ilonen J; Järvenpää S; Luukkainen R; Hannonen P
Clin Exp Rheumatol; 2011; 29(3):500-5. PubMed ID: 21640044
[TBL] [Abstract][Full Text] [Related]
15. Palindromic rheumatism with positive anticitrullinated peptide/protein antibodies is not synonymous with rheumatoid arthritis. A longterm followup study.
Sanmartí R; Cabrera-Villalba S; Gómez-Puerta JA; Ruiz-Esquide V; Hernández MV; Salvador G; Ramirez J; Viñas O; Cañete JD
J Rheumatol; 2012 Oct; 39(10):1929-33. PubMed ID: 22859345
[TBL] [Abstract][Full Text] [Related]
16. Differential response of the rheumatoid factor and anticitrullinated protein antibodies during adalimumab treatment in patients with rheumatoid arthritis.
Bos WH; Bartelds GM; Wolbink GJ; de Koning MH; van de Stadt RJ; van Schaardenburg D; Dijkmans BA; Nurmohamed MT
J Rheumatol; 2008 Oct; 35(10):1972-7. PubMed ID: 18785316
[TBL] [Abstract][Full Text] [Related]
17. Inflammation and autoantibody markers identify rheumatoid arthritis patients with enhanced clinical benefit following rituximab treatment.
Lal P; Su Z; Holweg CT; Silverman GJ; Schwartzman S; Kelman A; Read S; Spaniolo G; Monroe JG; Behrens TW; Townsend MJ
Arthritis Rheum; 2011 Dec; 63(12):3681-91. PubMed ID: 22127691
[TBL] [Abstract][Full Text] [Related]
18. Changes in the anticitrullinated peptide antibody response in relation to therapeutic outcome in early rheumatoid arthritis: results from the SWEFOT trial.
Kastbom A; Forslind K; Ernestam S; Geborek P; Karlsson JA; Petersson IF; Saevarsdottir S; Klareskog L; van Vollenhoven RF; Lundberg K
Ann Rheum Dis; 2016 Feb; 75(2):356-61. PubMed ID: 25550338
[TBL] [Abstract][Full Text] [Related]
19. Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries.
Chatzidionysiou K; Lie E; Nasonov E; Lukina G; Hetland ML; Tarp U; Gabay C; van Riel PL; Nordström DC; Gomez-Reino J; Pavelka K; Tomsic M; Kvien TK; van Vollenhoven RF
Ann Rheum Dis; 2011 Sep; 70(9):1575-80. PubMed ID: 21571731
[TBL] [Abstract][Full Text] [Related]
20. Risk of progression from undifferentiated arthritis to rheumatoid arthritis: the effect of the PTPN22 1858T-allele in anti-citrullinated peptide antibody positive patients.
Feitsma AL; Toes RE; Begovich AB; Chokkalingam AP; de Vries RR; Huizinga TW; van der Helm-van Mil AH
Rheumatology (Oxford); 2007 Jul; 46(7):1092-5. PubMed ID: 17341507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
